Subscribe free

HPB & Spleen ·

Adjuvant PD-1 inhibitors enhance survival in high-risk HCC patients.

In a study involving 199 hepatocellular carcinoma patients, the use of adjuvant PD-1 inhibitors significantly improved both recurrence-free survival (RFS) and overall survival (OS) rates. After propensity score matching, 1-year RFS was 87.1% for those receiving PD-1 inhibitors versus 44.6% for non-recipients, while 1-year OS rates were 98.5% versus 90.7%, respectively. The findings suggest that PD-1 inhibitors may effectively mitigate tumor recurrence and enhance survival outcomes post-hepatectomy.

Journal Article by Shen X, Yan W (…) Dong H et 3 al. in Eur J Med Res

© 2025. The Author(s).

read the whole article in Eur J Med Res

open it in PubMed

Summaries are written to help you decide what to read. They do not replace the full paper.

Free · 5 minutes a day

Get every new paper in HPB & Spleen.

Plus the Daily Selection: the five most relevant papers of the day, each cut to its key points.

Specialty newsletters: every new paper in your field, as a list of titles linked to the source. Daily Selection: the five that matter, cut to their key points.

FreeNo spamOne-click unsubscribe

More in HPB & Spleen

The latest stitches

Surg Endosc6 Nov 2026

A new cut for robotic liver surgery

A close-to-open cutting method was used for robotic liver resection, with no bile leaks and shorter hospital stays than after laparoscopy.

Surg Endosc6 Nov 2026

Robotic bile duct stone surgery: fewer complications

Removing large common bile duct stones with a robot rather than laparoscopically was linked to fewer complications and shorter hospital stays, at a higher cost, in a study from one Chinese hospital.

All papers in HPB & Spleen →